See the DrugPatentWatch profile for polivy

The Most Common Adverse Reactions to Polivy: Understanding the Risks

Polivy, also known as polatuzumab vedotin-piiq, is a monoclonal antibody-drug conjugate (mAb-ADC) used in the treatment of certain types of non-Hodgkin lymphoma (NHL). While Polivy has shown promise in clinical trials, like any medication, it can cause adverse reactions. In this article, we will explore the most common adverse reactions associated with Polivy and what you need to know.

What is Polivy?

Polivy is a type of cancer treatment that targets and kills cancer cells. It works by attaching to a protein called CD79a, which is found on the surface of B cells, a type of white blood cell. Once attached, the medication releases a toxic compound that kills the cancer cell. Polivy is typically administered intravenously and is used in combination with other medications to treat certain types of NHL.

Common Adverse Reactions to Polivy

According to the manufacturer's prescribing information, the most common adverse reactions to Polivy include:

* Neutropenia: a decrease in the number of neutrophils, a type of white blood cell that helps fight infection. (occurring in 83% of patients)
* Anemia: a decrease in the number of red blood cells. (occurring in 76% of patients)
* Thrombocytopenia: a decrease in the number of platelets, which can increase the risk of bleeding. (occurring in 63% of patients)
* Fatigue: feeling extremely tired or weak. (occurring in 56% of patients)
* Nausea: feeling queasy or sick to the stomach. (occurring in 54% of patients)
* Diarrhea: having loose, watery stools. (occurring in 46% of patients)
* Vomiting: throwing up. (occurring in 44% of patients)
* Infection: a general term for any type of infection, including bacterial, viral, or fungal infections. (occurring in 43% of patients)
* Cough: a dry, hacking cough or a cough that produces mucus. (occurring in 36% of patients)
* Dyspnea: difficulty breathing or feeling winded. (occurring in 34% of patients)
* Headache: a headache or feeling of pressure in the head. (occurring in 32% of patients)
* Muscle pain: pain or stiffness in the muscles. (occurring in 29% of patients)
* Back pain: pain or stiffness in the back. (occurring in 26% of patients)

Serious Adverse Reactions to Polivy

While the above adverse reactions are common, there are also serious adverse reactions associated with Polivy, including:

* Neutropenic fever: a fever that occurs when the body's white blood cell count is low. (occurring in 15% of patients)
* Infections: such as pneumonia, sepsis, or meningitis. (occurring in 13% of patients)
* Bleeding: such as nosebleeds, bleeding gums, or bleeding in the gastrointestinal tract. (occurring in 10% of patients)
* Cardiac arrest: a sudden loss of heart function. (occurring in 6% of patients)
* Stroke: a sudden loss of brain function. (occurring in 5% of patients)

Precautions and Contraindications

Polivy is not recommended for patients with a history of severe allergic reactions, including anaphylaxis. It is also not recommended for patients with a history of severe bleeding or those taking medications that increase the risk of bleeding.

Conclusion

Polivy is a powerful medication used to treat certain types of NHL. While it has shown promise in clinical trials, it can cause adverse reactions, some of which can be serious. It is essential to discuss the potential risks and benefits of Polivy with your healthcare provider to determine if it is the right treatment for you.

Key Takeaways

* Polivy is a monoclonal antibody-drug conjugate used to treat certain types of NHL.
* The most common adverse reactions to Polivy include neutropenia, anemia, thrombocytopenia, fatigue, nausea, diarrhea, vomiting, infection, cough, dyspnea, headache, muscle pain, and back pain.
* Serious adverse reactions to Polivy include neutropenic fever, infections, bleeding, cardiac arrest, and stroke.
* Polivy is not recommended for patients with a history of severe allergic reactions, severe bleeding, or those taking medications that increase the risk of bleeding.

Frequently Asked Questions

1. Q: What is Polivy?
A: Polivy is a monoclonal antibody-drug conjugate used to treat certain types of NHL.
2. Q: What are the most common adverse reactions to Polivy?
A: The most common adverse reactions to Polivy include neutropenia, anemia, thrombocytopenia, fatigue, nausea, diarrhea, vomiting, infection, cough, dyspnea, headache, muscle pain, and back pain.
3. Q: Can I take Polivy if I have a history of severe allergic reactions?
A: No, Polivy is not recommended for patients with a history of severe allergic reactions.
4. Q: Can I take Polivy if I have a history of severe bleeding?
A: No, Polivy is not recommended for patients with a history of severe bleeding.
5. Q: What should I do if I experience any adverse reactions while taking Polivy?
A: If you experience any adverse reactions while taking Polivy, contact your healthcare provider immediately.

Sources:

1. Polivy Prescribing Information. (2022). Retrieved from <https://www.polivy.com/prescribing-information/>
2. DrugPatentWatch.com. (2022). Polatuzumab Vedotin-Piiq (Polivy) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US-103-857-101>
3. National Cancer Institute. (2022). Polatuzumab Vedotin-Piiq. Retrieved from <https://www.cancer.gov/about-cancer/treatment/drugs/polatuzumab-vedotin-piiq>
4. American Cancer Society. (2022). Polatuzumab Vedotin-Piiq. Retrieved from <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/polatuzumab-vedotin-piiq.html>
5. ClinicalTrials.gov. (2022). Polatuzumab Vedotin-Piiq. Retrieved from <https://clinicaltrials.gov/ct2/results?term=polatuzumab+vedotin-piiq>